Back

Regioselectively Acetylated Silybin Derivatives and their Cytotoxic Activity in Liver Cancer Cells

Tran, C. V.; Tran, T. T. P.; Nguyen, A. T.; Loc, T. V.; Garrett, M. D.; Do, T. T.; Serpell, C.; Tran, S. V.

2025-02-17 pharmacology and toxicology
10.1101/2025.02.13.638106 bioRxiv
Show abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=48 SRC="FIGDIR/small/638106v1_ufig1.gif" ALT="Figure 1"> View larger version (11K): org.highwire.dtl.DTLVardef@13744c8org.highwire.dtl.DTLVardef@184bb9borg.highwire.dtl.DTLVardef@138f442org.highwire.dtl.DTLVardef@2c45ca_HPS_FORMAT_FIGEXP M_FIG C_FIG Natural products continue to serve as a valuable source of starting points for therapeutic agents. Six silybin derivatives have been synthesized and tested in vitro for their cytotoxic effect on the human hepatocellular carcinoma line HepG2 using the MTT assay. Results indicate that the 3,5,7,20,23-penta-O-acetyl-2,3-dehydrosilybin possesses a stronger cytotoxic effect than that of the parent silybin by a factor of 12. This compound was further evaluated for its cytotoxic activity on Hep3B, Huh7, and Huh7R hepatocellular carcinoma cell lines, giving similar potencies, arresting the cell cycle at S phase and causing apoptosis. These results illustrate the potential of silybin derivatives as therapeutics against liver cancer.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.